title: Opportunities and limitations of drug-coated balloons in interventional therapies.
abstract: Drug-coated balloons (DCB) represent a novel clinical treatment modality for coronary and peripheral artery disease. Advantages over standard angioplasty and stent technologies including homogeneous drug delivery to the vessel wall, immediate drug release without the use of a polymer, the option of using balloon catheters alone or in combination with a bare metal stent, no foreign object that remains in the body, the potential of reducing antiplatelet therapy, and lower restenosis rates in some indications. As with drug-eluting stents (DES), one cannot assume a class effect for DCB. So far, data from randomized clinical trials identify the treatment of coronary in-stent restenosis (ISR) and of de novo and restenotic lesions in peripheral artery disease as viable options. Furthermore, treatment of de novo lesions in small coronary vessels, bifurcation lesions, long lesions, pediatric interventions, and cerebrovascular applications are potential beneficial indications. In the coronary application, a strategy of DCB angioplasty with provisional spot-stenting in the case of severe dissections may become a better alternative in long and complex lesions, bifurcations, or in patients with contraindications for DES.
authors.affiliation: Klinik für Innere Medizin III, Klinische und Experimentelle Interventionelle Kardiologie, Universitätsklinikum des Saarlandes, Homburg/Saar, Deutschland. Bruno.Scheller@uniklinikum-saarland.de
authors.forename: B
authors.initials: B
authors.lastname: Scheller
mesh_terms: D006328:Cardiac Catheterization / Q000295:instrumentation* / Q000639:trends*; D002404:Catheterization / Q000295:instrumentation* / Q000639:trends*; D003324:Coronary Artery Disease / Q000188:drug therapy*; D054855:Drug-Eluting Stents / Q000639:trends*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005544:Forecasting; D006801:Humans
chemical_list: D005343:Fibrinolytic Agents